A Phase I/Ib Study of Alisertib Plus R-EPOCH for Treatment of Myc-Positive Aggressive B-Cell Lymphomas
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 17 Jul 2017
At a glance
- Drugs Alisertib (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Prednisone; Rituximab; Vincristine
- Indications B cell lymphoma
- Focus Adverse reactions
- 11 Jul 2017 Status changed from suspended to active, no longer recruiting.
- 11 Jul 2017 Planned End Date changed from 1 Jan 2021 to 12 Feb 2019.
- 26 Apr 2017 Status changed from recruiting to suspended.